In her address to the membership, Joanne R. Barrick, RPh, Chair, noted that in 2021, implementation of the second year in ISPE’s current Strategic Plan will continue. “While we are changing the ‘how’ we deliver the strategic plan, the plan and our content priorities remain a solid foundation for our Society,” she emphasized. Digitization will enhance content and information availability, and Women in Pharma® and workforce development training programs will remain strong. The Society will continue to seek to expand its impact by increasing its global footprint, Barrick said, noting the recent addition of the Mexico and Eurasian Affiliates. She added that the ISPE Foundation is now poised for significant growth and will include the pursuit of initiatives targeted at increasing diversity in the pharmaceutical industry.
In addition, ISPE will continue to emphasize integration of conference, training, and guidance document offerings and place more emphasis on regulatory topic impact and activities, she said. Opportunities for more interface with the ISPE Board through conferences and participation in Chapter and Affiliate events can be expected.
ISPE delivers technical and operational solutions to support across the global pharmaceutical and biopharmaceutical industry in the manufacture of quality medicines for patients.
ISPE’s FOYA program recognizes state-of-the-art projects using innovative technologies to improve the quality of products, reduce the cost of producing high-quality medicines, and demonstrate advances in project delivery for the benefit of humanity.
ISPE has announced the establishment of the ISPE Radiopharmaceuticals Community of Practice (CoP). This initiative intends to respond to the rapid growth and unique complexities of the radiopharmaceuticals field, which is critically advancing precision medicine for conditions such as cancer.
Advanced therapy medicinal products (ATMPs) are redefining what’s possible in medicine, but their promise comes with a challenge the industry can no longer afford to postpone: how to scale manufacturing in a way that is cost-effective, resilient, and patient-ready.